Loading clinical trials...

Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT | Clinical Trials | Clareo Health

COMPLETEDPhase 1/2NCT01822093

Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT

Human Adenovirus-specific T-cells can persist and augment impaired adenovirus immune response post allogeneic haematopoietic stem cell transplant, and reduce the requirement for antiviral therapy with...

Lead sponsor: Cell Medica Ltd•3 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment8

Start dateDec 2012

Last updatedJan 25, 2018

Condition

ADV Infection Post Allo-HSCT

Locations shown

Great Ormond Street Hospital

London

Royal Manchester Children's Hospital

Manchester

Royal Victoria Infirmary

Newcastle

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 25, 2018Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions